Tags

Type your tag names separated by a space and hit enter

Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients.
Pharmacol Res Perspect. 2020 08; 8(4):e00631.PR

Abstract

We propose a new hypothesis that the established drug pentoxifylline deserves attention as a potential repurposed therapeutic for COVID-19. Pentoxifylline is an immunomodulator with anti-inflammatory properties. It is a nonselective phosphodiesterase inhibitor and through Adenosine A2A Receptor-mediated pathways reduces tumor necrosis factor alpha, interleukin 1, interleukin 6, and interferon gamma and may act to reduce tissue damage during the cytokine storm host response to SARS-CoV-2 infection. This agent has been used clinically for many years and has a favorable profile of safety and tolerability. Pre-clinical data support pentoxifylline as effective in cytokine-driven lung damage. Clinical studies of pentoxifylline in radiation and cytokine-induced lung damage in humans are positive and consistent with anti-inflammatory efficacy. Pentoxifylline is a readily available, off-patent and inexpensive drug, suitable for large-scale use including in resource-limited countries. Current trials of therapeutics are largely focused on the inhibition of viral processes. We advocate urgent randomized trials of pentoxifylline for COVID-19 as a complementary approach to target the host responses.

Authors+Show Affiliations

Renal Sciences, Department of Inflammation Biology, King's College London, London, UK.Department of Gastroenterology, Ealing Hospital, London North West University Healthcare NHS Trust, Southall, UK.National Heart and Lung Institute, Imperial College London, London, UK.Department of Gastroenterology, Ealing Hospital, London North West University Healthcare NHS Trust, Southall, UK.Department of Gastroenterology, Ealing Hospital, London North West University Healthcare NHS Trust, Southall, UK.National Heart and Lung Institute, Imperial College London, London, UK.Department of Gastroenterology, Ealing Hospital, London North West University Healthcare NHS Trust, Southall, UK.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32715661

Citation

Hendry, Bruce M., et al. "Hypothesis: Pentoxifylline Is a Potential Cytokine Modulator Therapeutic in COVID-19 Patients." Pharmacology Research & Perspectives, vol. 8, no. 4, 2020, pp. e00631.
Hendry BM, Stafford N, Arnold AD, et al. Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients. Pharmacol Res Perspect. 2020;8(4):e00631.
Hendry, B. M., Stafford, N., Arnold, A. D., Sangwaiya, A., Manglam, V., Rosen, S. D., & Arnold, J. (2020). Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients. Pharmacology Research & Perspectives, 8(4), e00631. https://doi.org/10.1002/prp2.631
Hendry BM, et al. Hypothesis: Pentoxifylline Is a Potential Cytokine Modulator Therapeutic in COVID-19 Patients. Pharmacol Res Perspect. 2020;8(4):e00631. PubMed PMID: 32715661.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients. AU - Hendry,Bruce M, AU - Stafford,Nina, AU - Arnold,Ahran D, AU - Sangwaiya,Arvind, AU - Manglam,Vijay, AU - Rosen,Stuart D, AU - Arnold,Jayantha, PY - 2020/06/29/received PY - 2020/07/01/revised PY - 2020/07/02/accepted PY - 2020/7/28/entrez PY - 2020/7/28/pubmed PY - 2020/8/5/medline KW - COVID-19 KW - SARS-CoV-2 KW - cytokine KW - immunomodulation KW - pentoxifylline KW - pneumonia KW - viral SP - e00631 EP - e00631 JF - Pharmacology research & perspectives JO - Pharmacol Res Perspect VL - 8 IS - 4 N2 - We propose a new hypothesis that the established drug pentoxifylline deserves attention as a potential repurposed therapeutic for COVID-19. Pentoxifylline is an immunomodulator with anti-inflammatory properties. It is a nonselective phosphodiesterase inhibitor and through Adenosine A2A Receptor-mediated pathways reduces tumor necrosis factor alpha, interleukin 1, interleukin 6, and interferon gamma and may act to reduce tissue damage during the cytokine storm host response to SARS-CoV-2 infection. This agent has been used clinically for many years and has a favorable profile of safety and tolerability. Pre-clinical data support pentoxifylline as effective in cytokine-driven lung damage. Clinical studies of pentoxifylline in radiation and cytokine-induced lung damage in humans are positive and consistent with anti-inflammatory efficacy. Pentoxifylline is a readily available, off-patent and inexpensive drug, suitable for large-scale use including in resource-limited countries. Current trials of therapeutics are largely focused on the inhibition of viral processes. We advocate urgent randomized trials of pentoxifylline for COVID-19 as a complementary approach to target the host responses. SN - 2052-1707 UR - https://www.unboundmedicine.com/medline/citation/32715661/Hypothesis:_Pentoxifylline_is_a_potential_cytokine_modulator_therapeutic_in_COVID_19_patients_ L2 - https://doi.org/10.1002/prp2.631 DB - PRIME DP - Unbound Medicine ER -